Turn Therapeutics Issues Updated Investor Presentation Amid Pipeline Progression

Investor Presentation Filed Under Regulation FD

On July 28, 2026, Turn Therapeutics Inc. disclosed an updated investor presentation via a filing with the Securities and Exchange Commission. The presentation was included as Exhibit 99.1 in the company's current report, signed by CEO Bradley Burnam on the same date. This update aims to provide stakeholders with timely information regarding the company’s operations and strategic direction.

The filing was made pursuant to Regulation FD (Fair Disclosure), which mandates that material information be disseminated simultaneously to all investors. By utilizing this disclosure method, Turn Therapeutics ensured equal access to the updated corporate information across the market.

Corporate Profile and Status of Turn Therapeutics

Turn Therapeutics Inc. is incorporated in Delaware, with its principal executive offices located at 250 North Westlake Boulevard, Westlake Village, California. The company’s Commission File Number is 001-42875, and its IRS Employer Identification Number is 32-0456090. Its common stock trades on The Nasdaq Stock Market LLC under the symbol TTRX, with a par value of $0.0001 per share.

Classified as an emerging growth company under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, Turn Therapeutics has opted not to use the extended transition period for adopting new or revised financial accounting standards, adhering instead to the standard compliance schedule applicable to public companies.

CEO Authorization and Filing Specifics

Bradley Burnam, Turn Therapeutics’ Chief Executive Officer, authorized the current report filing on July 28, 2026. His signature on the document satisfies the requirements of the Securities Exchange Act of 1934, ensuring proper disclosure of material corporate events to shareholders and the investing public.

The filing notes the earliest reported event date as July 28, 2026, coinciding with the release date of the updated investor presentation. This synchronization provides clarity for investors and regulators regarding the timing of the disclosure relative to market activity.

Details and Purpose of the Investor Presentation

The updated investor presentation serves as a communication tool to inform investors about Turn Therapeutics’ business operations, pipeline progress, and strategic objectives. While the filing does not detail the presentation’s content, its significance warranted formal SEC disclosure via Regulation FD.

The presentation is provided as interactive data in an Inline XBRL format within the regulatory filing, facilitating accessibility for investors, analysts, and other stakeholders through the SEC’s EDGAR system and promoting transparency and equal information distribution.

Trading and Market Information

Turn Therapeutics’ common stock is publicly traded on The Nasdaq Stock Market LLC under the ticker TTRX. The company maintains a registered class of securities under Section 12(b) of the Securities Exchange Act of 1934, subject to ongoing reporting and corporate governance requirements. Each share carries a par value of $0.0001.

As a Nasdaq-listed entity, Turn Therapeutics complies with the exchange’s listing standards and disclosure obligations. The July 28, 2026 investor presentation forms part of the company’s broader investor relations efforts to sustain transparent communication with shareholders and the financial community. No immediate impact on share price was evident from publicly available information.

Legal Status of the Disclosure

The current report clarifies that the information in Item 7.01, including Exhibit 99.1 investor presentation, is not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to related liabilities. This standard Regulation FD language delineates the legal standing of the furnished materials.

Furthermore, the filing specifies that the disclosure is not incorporated by reference into any other filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, except where explicitly stated. This ensures clarity on the regulatory framework governing the presentation’s use in future filings.

Emerging Growth Company Status and Regulatory Impact

Turn Therapeutics’ emerging growth company classification under federal securities laws grants certain scaled disclosure and compliance accommodations designed to ease regulatory burdens for smaller public companies. This status influences the company’s financial reporting, executive compensation disclosures, and other SEC filings.

The company’s choice not to adopt the extended transition period for new accounting standards means it aligns with larger companies on the timeline for implementing changes to Generally Accepted Accounting Principles, underscoring its commitment to consistent financial reporting.

Corporate Contact and Operations

Turn Therapeutics’ main executive office is located at 250 North Westlake Boulevard, Westlake Village, California 91362. The regulatory filing lists the company’s phone number as (818) 564-4011, providing a direct line for investor, analyst, and regulatory communications.

The filing reports no changes to the company’s name or address since the last report, indicating stability in its corporate identity and principal place of business, which supports continuity for investors monitoring the company’s progress and compliance.

Investor Outlook and Forward-Looking Information

The updated investor presentation offers current corporate insights valuable to existing shareholders and potential investors assessing Turn Therapeutics. While the filing does not specify presentation details, it likely covers the company’s strategic plans, clinical pipeline status, financial condition, and growth outlook.

Investors and analysts are encouraged to review the full investor presentation via the SEC’s EDGAR database for comprehensive information on Turn Therapeutics’ operations and strategic initiatives. The presentation reflects management’s current perspectives on business development and market positioning, providing useful context for evaluating the company’s future prospects.